Twitter feed

Attend the #AACR23 Cancer and Biomedical Research Career Fair on April 15 in Orlando. Scientists at all career levels can meet with organizations seeking to fill scientific positions. Upload your CV/resume and attend for a chance to win great prizes.

Today, the @US_FDA granted accelerated approval to pirtobrutinib, a targeted therapy for adult patients with relapsed or refractory mantle cell lymphoma after two or more systemic therapies.

FDA grants accelerated approval to pirtobrutinib

FDA grants accelerated approval to pirtobrutinib for relapsed or refractory mantle cell lymphoma


Today the @US_FDA approved the targeted therapeutic elacestrant to treat certain postmenopausal women or adult men with advanced or metastatic ER-positive, HER2-negative,ESR1-mutated breast cancer after one or more lines of endocrine therapy.

FDA approves elacestrant for ER-positive

FDA approves elacestrant for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer


New #ColonCancer research: Investigators found higher inflammation after diagnosis was associated with an increased risk of recurrence and death. Research led by @DanaFarber's Jeffrey Meyerhardt, MD, in @JAMAOnc
CC: @EnCheng23 @DFarberYoungCRC
Read more:

Association of Inflammatory Biomarkers With Survival Among Patients With Stage III Colon Cancer

This cohort study assesses the association between survival outcomes and levels of inflammatory biomarkers after diagnosis with stage III colon cancer...


While the past decade has brought progress against cervical cancer, challenges remain, especially for older women and those in lower- and middle-income countries. Learn more on the #AACRBlog. @CancerTodayMag @CEBP_AACR #CervicalCancerAwarenessMonth https://t.co/zSN7vo8fFb

Register by February 1 to get the lowest rates for the AACR Special Conference on Advances in Prostate Cancer Research (March 15-18, 2023; Denver), chaired by Cory Abate-Shen, @felixfengmd, and Scott A. Tomlins. Learn more:

Deborah Schrag, David @DeNardoLabWUSM, @tomi_akinyemiju, Robert Yarchoan, and @TeresaZimmers will present their cutting-edge research in the Opening Plenary Session at the AACR Annual Meeting 2023 (April 14-19, Orlando, Florida). Learn more:

Recent publications

MET-induced CD73 restrains STING-mediated immunogenicity of EGFR-mutant lung cancer.
Cancer Res. 2022 Sep 6

Quinazolinones as allosteric fourth-generation EGFR inhibitors for the treatment of NSCLC.
Bioorg Med Chem Lett. 2022 Jul 15.

All publications



Target identification and validation image
Target identification and validation
Photo of scientist carefully adding fluid to multiple test tubes
Drug discovery and development
Photo of Belfer Center researcher working at computer
Clinical science and correlatives

Strategic alliances

Graphic showing circular relationship of research, medicine, and industry

Our strategic alliances drive research innovations and lead to improved therapies to benefit cancer patients

Collaborate with us

Our people

Background image is a collage of photos showing Belfer Center members
Our team
Our culture
Background image is a collage of photos showing Belfer Center members

Donor highlight

Robert and Renée Belfer’s transformative cumulative Dana-Farber investment of more than $25 million launched the Robert A. and Renée E. Belfer Center for Applied Cancer Science. Their generosity enabled the Belfer Center to integrate its scientific teams, produce innovative cancer models, partner with industry leaders, and accelerate the development of revolutionary therapies to treat cancer. We are grateful for their vision and incredible support.

Photo of donors, Mr. and Mrs Belfer
Go to Top